Avalyn Pharma (NASDAQ:AVLN) Sets New 52-Week Low – What’s Next?

Avalyn Pharma Inc. (NASDAQ:AVLN) hit a new 52-week low on Wednesday. The company traded as low as $23.08 and last traded at $23.74, with a volume of 403,934 shares trading hands. The stock had previously closed at $24.80.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen lowered Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Raymond James Financial assumed coverage on Avalyn Pharma in a research report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 target price for the company. Morgan Stanley lifted their target price on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings initiated coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They set a “sell (d+)” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Avalyn Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Avalyn Pharma Trading Down 4.3%

The firm has a market cap of $1.05 billion and a P/E ratio of -1.04. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $33.04.

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.05. On average, analysts anticipate that Avalyn Pharma Inc. will post -3.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AVLN. Montanova Capital LLC acquired a new position in Avalyn Pharma during the 2nd quarter worth $82,402,000. Braidwell LP acquired a new stake in Avalyn Pharma in the 2nd quarter valued at about $26,382,000. State Street Corp acquired a new stake in Avalyn Pharma in the 2nd quarter valued at about $10,501,000. Finally, Bank of New York Mellon Corp acquired a new stake in Avalyn Pharma in the 2nd quarter valued at about $1,321,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.